

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	1
<b>LIST OF PARTICIPANTS</b> .....	3
<b>PREAMBLE</b> .....	9
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. Data for the <i>Monographs</i> .....	12
5. Meeting participants.....	12
6. Working procedures.....	13
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References.....	31
<b>GENERAL REMARKS</b> .....	33
<b>DDT</b> .....	37
1. Exposure Data.....	37
1.1. Identification of the agent.....	37
1.2. Production and use.....	38
1.3. Measurement and analysis.....	43
1.4. Occurrence and exposure.....	43
1.5. Regulation.....	74

2. Cancer in Humans .....	76
2.1 Cohort studies .....	76
2.2 Case-control studies .....	107
3. Cancer in Experimental Animals .....	158
3.1 Mouse .....	158
3.2 Rat .....	173
3.3 Hamster .....	176
3.4 Monkey .....	177
3.5 Carcinogenicity of metabolites of DDT .....	177
4. Mechanistic and Other Relevant Data .....	179
4.1 Toxicokinetic data .....	179
4.2 Mechanisms of carcinogenesis .....	184
4.3 Data relevant to comparisons across agents and end-points .....	215
4.4 Cancer susceptibility data .....	220
4.5 Other adverse effects .....	227
5. Summary of Data Reported .....	228
5.1 Exposure data .....	228
5.2 Human carcinogenicity data .....	229
5.3 Animal carcinogenicity data .....	230
5.4 Mechanistic and other relevant data .....	231
6. Evaluation .....	233
6.1 Cancer in humans .....	233
6.2 Cancer in experimental animals .....	233
6.3 Overall evaluation .....	233
6.4 Rationale .....	233
References .....	233
<b>LINDANE</b> .....	267
1. Exposure Data .....	267
1.1 Identification of the agent .....	267
1.2 Production and use .....	268
1.3 Measurement and analysis .....	269
1.4 Occurrence and exposure .....	270
1.5 Regulation .....	289
2. Cancer in Humans .....	290
2.1 Cohort studies .....	290
2.2 Case-control studies nested within cohorts .....	297
2.3 Case-control studies .....	299
2.4 Meta-analysis .....	312
3. Cancer in Experimental Animals .....	312
3.1 Mouse .....	312
3.2 Rat .....	320
4. Mechanistic and Other Relevant Data .....	321
4.1 Toxicokinetics .....	321
4.2 Mechanisms of carcinogenesis .....	324
4.3 Data relevant to comparisons across agents and end-points .....	341
4.4 Cancer susceptibility data .....	349

---

4.5 Other adverse effects .....	349
5. Summary of Data Reported .....	353
5.1 Exposure data.....	353
5.2 Human carcinogenicity data.....	354
5.3 Animal carcinogenicity data.....	354
5.4 Mechanistic and other relevant data.....	355
6. Evaluation.....	356
6.1 Cancer in humans.....	356
6.2 Cancer in experimental animals.....	356
6.3 Overall evaluation .....	356
References.....	356
<b>2,4-DICHLOROPHENOXYACETIC ACID.....</b>	<b>373</b>
1. Exposure Data.....	373
1.1 Identification of the agent .....	373
1.2 Production and use.....	374
1.3 Measurement and analysis.....	376
1.4 Occurrence and exposure.....	377
1.5 Regulation.....	399
2. Cancer in Humans .....	401
2.1 Cohort studies .....	401
2.2 Case-control studies .....	407
2.3 Meta-analyses .....	422
3. Cancer in Experimental Animals .....	429
3.1 Mouse.....	429
3.2 Rat .....	435
3.3 Dog .....	437
4. Mechanistic and Other Relevant Data .....	439
4.1 Toxicokinetics .....	439
4.2 Mechanisms of carcinogenesis.....	441
4.3 Data relevant to comparisons across agents and end-points .....	465
4.4 Cancer susceptibility data .....	471
4.5 Other adverse effects .....	471
5. Summary of Data Reported .....	477
5.1 Exposure data.....	477
5.2 Human carcinogenicity data.....	477
5.3. Animal carcinogenicity data.....	478
5.4 Mechanistic and other relevant data.....	479
6. Evaluation.....	480
6.1 Cancer in humans.....	480
6.2 Cancer in experimental animals.....	480
6.3 Overall evaluation .....	480
References.....	480
<b>LIST OF ABBREVIATIONS .....</b>	<b>499</b>
<b>ANNEX 1. SUPPLEMENTAL MATERIAL .....</b>	<b>503</b>



## NOTE TO THE READER

---

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.